Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued developmentBudoprutug pMN, ...
Climb Bio (NASDAQ:CLYM) used an investor R&D spotlight event to outline its strategy around CD19-targeted B-cell depletion ...
Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued developmentCLYM116 modeling ...
ADI-001 is an allogeneic gamma delta CAR T-cell therapy that targets the B-cell antigen CD20. The Food and Drug Administration (FDA) has granted Fast Track designation to ADI-001 for the treatment of ...
We read with great interest the recent article by Tsai et al,1 which compared characteristics between primary neuromyelitis ...
CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic and musculoskeletal diseases (RMD). This and other cell-depleting approaches ...
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organs. SLE severity is highly variable, and this variability is known to be partially dependent on ancestral ...
MDX2003 targets CD19 and CD20 on B cells and CD3 and CD28 on T cells, enhancing antitumor activity and reducing antigen loss. The therapy's design limits cytokine release syndrome, showing improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results